155 related articles for article (PubMed ID: 34164164)
1. Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy.
Alves A; Dias M; Campainha S; Barroso A
J Thorac Dis; 2021 May; 13(5):2716-2727. PubMed ID: 34164164
[TBL] [Abstract][Full Text] [Related]
2. Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma.
Kartolo A; Holstead R; Hopman W; Baetz T
Immunotherapy; 2021 Feb; 13(3):217-225. PubMed ID: 33238773
[No Abstract] [Full Text] [Related]
3. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
4. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Li L; Xu F; Chen Y; Ren X; Liu Y; Chen Y; Xia S
BMJ Open; 2020 Nov; 10(11):e034010. PubMed ID: 33444168
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
7. Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy.
Caliman E; Fancelli S; Ottanelli C; Mazzoni F; Paglialunga L; Lavacchi D; Michelet MRG; Giommoni E; Napolitano B; Scolari F; Voltolini L; Comin CE; Pillozzi S; Antonuzzo L
Cancer Treat Res Commun; 2022; 32():100603. PubMed ID: 35792426
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
Moreira A; Leisgang W; Schuler G; Heinzerling L
Immunotherapy; 2017 Jan; 9(2):115-121. PubMed ID: 28128709
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
[TBL] [Abstract][Full Text] [Related]
10. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang L; Li L; Zhou Y; Yang Z; Wang M; Gao Y; Yang Y; Yang F; Liu B; Hong X; Chen G
J Cancer; 2020; 11(24):7137-7145. PubMed ID: 33193876
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
13. Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
Li Y; Zhang Y; Jia X; Jiang P; Mao Z; Liang T; Du Y; Zhang J; Zhang G; Niu G; Guo H
Clin Lung Cancer; 2021 Nov; 22(6):e889-e900. PubMed ID: 34183265
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
Sonehara K; Tateishi K; Araki T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Oncology; 2021; 99(5):271-279. PubMed ID: 33631764
[TBL] [Abstract][Full Text] [Related]
15. Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer.
Wu Y; Li D; Wu M; Yang Y; Shen M; Chen K
Front Oncol; 2022; 12():1004663. PubMed ID: 36313675
[TBL] [Abstract][Full Text] [Related]
16. [Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Xia J; Chen Y; Wen S; Du X; Shen B
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
[TBL] [Abstract][Full Text] [Related]
17. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
20. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Prelaj A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Mensah M; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Trevisan B; Trovò F; Torri V; Sozzi G; Garassino MC; Boeri M
Transl Lung Cancer Res; 2020 Jun; 9(3):617-628. PubMed ID: 32676324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
